OncoMatch/Clinical Trials/NCT06290687
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
Is NCT06290687 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant Chemotherapy and Adjuvant systemic therapy for malignant neoplasm of bladder.
Treatment: Neoadjuvant Chemotherapy · Adjuvant systemic therapy — The goal of this clinical trial is to determine if a partial cystectomy with extended pelvic lymph node removal will be effective at treating Muscle-Invasive Bladder Cancer instead of a complete cystectomy with extended pelvic lymph node removal. This clinical trial aims to determine the safety and oncologic efficacy of the intervention, and to examine patient-reported quality of life outcomes in participants. Participants will receive the standard pre-surgery treatment for approximately 4 to 6 weeks. After the pre-surgery treatment is completed, participants will undergo a partial cystectomy with extended pelvic lymph node dissection. After surgery, participants will receive adjuvant systemic therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Urothelial Carcinoma
Disease stage
Excluded: Stage M+, CT4+
clinical stage T2-3N0M0; Presence of clinical N+ or M+ disease [excluded]; Presence of cT4+ disease [excluded]
Performance status
KARNOFSKY OR ECOG 0–1
Karnofsky Performance Status ≥70 or Eastern Cooperative Oncology Group (ECOG) performance status Grade 0 or 1
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1,500/mm3; Platelet count ≥ 80,000/mm3; Hemoglobin ≥ 9.0 g/dL
Liver function
Total bilirubin within normal limits; AST (SGOT) ≤ 2.5 X institutional upper limit of normal; ALT (SGPT) ≤ 2.5 X institutional upper limit of normal
Subjects must have normal organ and marrow function as defined below: Total bilirubin within normal limits; AST (SGOT) ≤ 2.5 X institutional upper limit of normal; ALT (SGPT) ≤ 2.5 X institutional upper limit of normal; Bone marrow: Absolute neutrophil count (ANC) ≥ 1,500/mm3; Platelet count ≥ 80,000/mm3, Hemoglobin ≥ 9.0 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Glickman Urological and Kidney Institute, Cleveland Clinic, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify